ZYXI vs STIM vs ENVA vs GMED vs ABT

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus 4. 4% for Zynex, Inc. (ZYXI). Zynex, Inc. (ZYXI) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zynex, Inc.

(ZYXI) is the cheapest at 0. 6x versus Globus Medical, Inc. at 21. 7x. On forward P/E, Enova International, Inc. is actually cheaper at 10. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 53x versus Globus Medical, Inc. 's 0. 61x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Enova International, Inc.

(ENVA) delivered a total return of +368. 1%, compared to -98. 9% for Zynex, Inc. (ZYXI). Over 10 years, the gap is even starker: ENVA returned +20. 3% versus STIM's -93. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus Zynex, Inc. 's 4. 55β — meaning ZYXI is approximately 1732% more volatile than ABT relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus 4. 4% for Zynex, Inc. (ZYXI). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -66. 7% for Zynex, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -26. 1% for Neuronetics, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENVA leads at 23. 5% versus -21. 1% for STIM. At the gross margin level — before operating expenses — ZYXI leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 53x versus Globus Medical, Inc. 's 0. 61x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Enova International, Inc. (ENVA) trades at 10. 5x forward P/E versus 19. 0x for Globus Medical, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STIM: 334. 8% to $8. 00.

In this comparison, ABT (2.

5% yield), ZYXI (0. 5% yield) pay a dividend. STIM, ENVA, GMED do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Neuronetics, Inc. (STIM) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, STIM: -93. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYXI (Healthcare) and STIM (Healthcare) and ENVA (Financial Services) and GMED (Healthcare) and ABT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYXI is a small-cap deep-value stock; STIM is a small-cap high-growth stock; ENVA is a small-cap high-growth stock; GMED is a mid-cap high-growth stock; ABT is a mid-cap deep-value stock. ZYXI, ABT pay a dividend while STIM, ENVA, GMED do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.